Status
Conditions
Treatments
About
ORBITA-2 is a double blinded randomised placebo-controlled trial comparing the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy. Follow-up will be at 12 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
ORBITA-2 will enrol patients who meet all 3 of the following criteria:
Angina or angina-equivalent symptoms
Anatomical evidence of significant coronary stenosis in at least one vessel, either: a. Invasive diagnostic coronary angiogram indicating ≥ 70% stenosis b. CT coronary angiography indicating ≥ 90% stenosis
Evidence of ischaemia, arising from at least one of the following options:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
439 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Rasha Al-Lamee, MRCP; Christopher A Rajkumar, MRCP
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal